Immune Thrombocytopenia Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Players- Protalex, Genosco, Biotest, Argenx, Biogen, Novartis, Octapharma, Amgen, and CSL Behring

June 22 02:11 2022
Immune Thrombocytopenia Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Players- Protalex, Genosco, Biotest, Argenx, Biogen, Novartis, Octapharma, Amgen, and CSL Behring
Delveinsight Business Research LLP
DelveInsight’s “Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Immune Thrombocytopenia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Immune Thrombocytopenia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Immune Thrombocytopenia: An Overview

Immune thrombocytopenia (ITP),  previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of immune thrombocytopenia stem from a low platelet count leading to excessive bleeding.

Immune Thrombocytopenia Market Key Facts

  • The total prevalent population Immune Thrombocytopenia in the seven major markets was approximately 180,400+ in 2017.

  • The total diagnosed prevalent cases in the 7MM were estimated to be approximately 147,100+ in 2017.

  • In 2017, there were around 63,700+ prevalent cases of ITP and approximately 53,300+ diagnosed prevalent cases of Immune Thrombocytopenia in the United States.

  • Japan had 27,000+ prevalent cases of Immune Thrombocytopenia in 2017.

  • The majority of cases of Immune Thrombocytopenia are female as compared to males in the 7MM.

  • There were a total of approximately 32,300+ females and around 20,900+ males diagnosed with cases of ITP in 2017 in the United States.

  • Among the European countries, the United Kingdom had the highest prevalent population of ITP followed by Italy. On the other hand, Spain had the lowest prevalent population in 2017.

Immune Thrombocytopenia Market

The Immune Thrombocytopenia (ITP) market size is expected to increase during the forecast period owing to the launch of upcoming therapies. There are many pipeline therapies under development for the treatment of patients with ITP.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Immune Thrombocytopenia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Immune Thrombocytopenia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Immune Thrombocytopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Immune Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Thrombocytopenia market or expected to get launched during the study period. The analysis covers Immune Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Immune Thrombocytopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Immune Thrombocytopenia Therapeutics Analysis

Some of the key companies in the Immune Thrombocytopenia (ITP) market include:

  • Octapharma USA 

  • Amgen

  • CSL Behring

  • Dova Pharmaceuticals 

  • Rigel Pharmaceuticals 

  • Zenyaku Kogyo

  • Novartis 

  • Takeda Pharmaceutical 

  • Biogen Idec 

  • Biotest 

  •  GC Pharma

  • Argenx 

  • Genosco

  • Jiangsu HengRui Medicine 

  • Kezar Life Sciences 

  • UCB Biopharma

  • Bristol-Myers Squibb

  • Principia Biopharma 

  • Protalex 

And many others.

Immune Thrombocytopenia Therapies covered in the report include:

  • BT-595

  • GC5101B

  • ARGX-113

  • SKI-O-703

  • KZR-616

  • Rozanolixizumab

  • PRN1008

  • PRTX-100

And others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Immune Thrombocytopenia Competitive Intelligence Analysis

4. Immune Thrombocytopenia Market Overview at a Glance

5. Immune Thrombocytopenia Disease Background and Overview

6. Immune Thrombocytopenia Patient Journey

7. Immune Thrombocytopenia Epidemiology and Patient Population

8. Immune Thrombocytopenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Immune Thrombocytopenia Unmet Needs

10. Key Endpoints of Immune Thrombocytopenia Treatment

11. Immune Thrombocytopenia Marketed Products

12. Immune Thrombocytopenia Emerging Therapies

13. Immune Thrombocytopenia Seven Major Market Analysis

14. Attribute Analysis

15. Immune Thrombocytopenia Market Outlook (7 major markets)

16. Immune Thrombocytopenia Access and Reimbursement Overview

17. KOL Views on the Immune Thrombocytopenia Market.

18. Immune Thrombocytopenia Market Drivers

19. Immune Thrombocytopenia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of content.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Preeclampsia Market
“Preeclampsia Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Preeclampsia market trends in 7MM.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States